A revived interest for aldosterone antagonists;Le renouveau des antagonistes de l'aldostérone

Revue Medicale Suisse

Volumn 2, Issue 78, 2006, Pages 2055-2058

  Waeber, Bernard ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; EPLERENONE; PRIMACTON; SPIRONOLACTONE;

CARDIOVASCULAR RISK; DRUG TOLERABILITY; ENDOCRINE DISEASE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FAILURE; REVIEW;

ALDOSTERONE ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; HYPOKALEMIA; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 33748933559     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol 2005;186:1-20.
2. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004;351:33-41.
3. Rossier BC, Pradervand S, Schild L, Hummler E. Epithelial sodium channel and the control of sodium balance: Interaction between genetic and environmental factors. Annu Rev Physiol 2002;64:877-97.
4. Persu A, Barbry P, Bassilana F, et al. Genetic analysis of the beta subunit of the epithelial Na+ channel in essential hypertension. Hypertension 1998;32:129-37.
5. Weber KT, Brilla CG. Pathological hypertrophy and the cardiac interstitium: Fibrosis and the renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65.
6. Kagawa CM, Cella JA, Van Arman CG. Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science 1957;126:1015-6.
7. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol 2000;61:52-60.
8. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15:709-16.
9. Jorde UP. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: Choice of agents and clinical impact Cardiol Rev 2006;14:81-7.
10. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-7.
11. Satoh M, Nakamura M, Saitoh H, et al. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin Sci 2002;102:381-6.
12. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
13. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
14. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700-6.
15. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005;46:425-31.
16. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51.
17. Pitt B. The role of aldosterone blockade in patients with heart failure. Heart Fail Rev 2005;10:79-83.
18. Calhoun DA. Use of aldosterone antagonists in resistant hypertension. Progress Cardiovasc Dis 2006;48:387-96.
19. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41:1148-55.
20. Burgess ED, Lacourciere Y, Ruilope-Urioste LM, et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 2003;25:2388-404.